IDBS and ChemAxon partnership harnesses leading biology and chemistry expertise

Strategic technology deal strengthens IDBS’ single R&D data management platform

Boston, US, Budapest, Hungary & London, UK, April 22, 2015 – Today at Bio-IT World Conference & Expo 2015, IDBS announces a strategic technology partnership which sees ChemAxon’s industry-leading chemical sciences software integrated into IDBS’ E-WorkBook and ActivityBase. The addition of these advanced chemical indexing and web rendering capabilities from ChemAxon complement IDBS’ deep-domain biology expertise and bolster its single, cross-domain platform, offering users the best technology for their chosen area of research.

Paul Denny-Gouldson, Vice President, Strategic Solutions, IDBS said, “ChemAxon is recognized as the best cheminformatics provider there is. Teaming up to enable our clients to benefit from this industry-leading software makes sense. The integration strengthens our existing chemical sciences technology and forms part of our growth strategy to partner with like-minded organizations, expanding our footprint and delivering more value to our clients. This approach signals our ongoing commitment to providing an end-to-end R&D data management platform which delivers on a global level across all scientific domains, chemistry and biology included.”

The ChemAxon indexing technology will be used to store all structural chemistry data and make it searchable across the IDBS platform. Clients can rationalize infrastructure, saving money and simplifying the IT environment. The move also accelerates IDBS’ web migration in this very scientifically complex field, and is a springboard which delivers new opportunities to both companies.

“We’re keen to make our tools available to research experts across varied sectors. This agreement will expose our technology to a wider range of customers and markets,” said Dr Ferenc Csizmadia, CEO, ChemAxon. “We’ve worked with IDBS to deliver various chemical representation and search add-ons for over five years. These will still be available, but this continuation takes our partnership to a completely new level of fully supported integration. It speaks volumes to the strength of our technology in the market.”

IDBS and ChemAxon have invested significant time and resource into this agreement. Customers will be the first to see the integration of ChemAxon’s technologies into E-WorkBook when it is unveiled at IDBS Connect in Philadelphia, USA, on May 19-20, 2015.

For more information on the technology partnership please visit IDBS at booth 454 & 456 and ChemAxon at booth 222 at Bio-IT World.

About ChemAxon

ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA and sales and support offices in Europe, Japan and across North America.

For further information please visit or follow us on Twitter @chemaxon.

About IDBS         

IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.

Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 250 staff across the world and serving over 50,000 researchers in 25 countries – including over 75% of the top twenty pharmaceutical companies.